IRCT20181005041243N1RecruitingPhase 2
Efficacy and safety of spironolactone 2% versus erythromycin 4% in treating patients with acne
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 90
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 40 years (—)
- Sex
- All
Inclusion Criteria
- •Aged 18-40
- •Acne diagnosis by a dermatologist
Exclusion Criteria
- •Pregnancy or breastfeeding during the intervention
- •history of internal diseases, including endocrine diseases causing acne
- •alteration in diet and lifestyle during the study
- •having consumed systemic therapy for acne in the last 4 weeks
- •having consumed oral antibiotics in the last 3 months
- •having consumed topical therapy for acne in the last 2 weeks
- •having consumed isotretinoin, undertaken laser, and peeling in the last 6 months
- •Photosensitivity
- •severe or nodularis acne
- •polycystic ovary syndrome
Investigators
Similar Trials
Recruiting
Phase 2
Comparing the effectiveness of spironolactone solution with clindamycin solution in patients with acneMild to moderate acne vulgaris.Acne vulgarisL70.0IRCT20120524009844N12Tabriz University of Medical Sciences60
Recruiting
Phase 3
Comparison between the effects of spironolactone and eplerenone in the treatment of heart failureIRCT20130422013090N4Sari University of Medical Sciences70
Completed
Phase 4
Comparison of the efficacy of Spironolcatone 5% and Progesterone 2% on hair density and diameter in female pattern hair lossFemale pattern andrpgenetic alopecia.Androgenic alopeciaIRCT201512252581N4Vice Chancellor for research, Tabriz University of Medical Sciences36
Terminated
Phase 2
Assessment of the use of spironolactone on the endothelial glycocalyx in patients with kidney transplantsKidney transplantRenal and Urogenital - Kidney diseaseACTRN12616000966493Department of Renal Medicine, Box Hill Hospital20
Completed
Not Applicable
combination therapy trial in COVID-19 patientsCOVID19.COVID-19, virus identifiedU07.1IRCT20201003048904N2Boushehr University of Medical Sciences200